paque 350
• Oral radiographic examination of the gastrointestinal tract. Pediatrics: Omnipaque 180, 240, and 300
• Oral and rectal radiographic examination of the gastrointestinal tract.
Oral administration in conjunction with intravenous administration: Diluted Omnipaque Injection–Adults: Omnipaque 240, 300, and 350 diluted and administered orally in conjunction with Omnipaque 300 administered intravenously
• CT of the abdomen. Pediatrics: Omnipaque 240, 300, and 350 diluted and administered orally in conjunction with Omnipaque 240 or Omnipaque 300 administered intravenously
• CT of the abdomen. Omnipaque Oral Solution – Adults: Omnipaque Oral Solutions 9 and 12 administered orally in conjunction with Omnipaque 300 administered intravenously
• CT of the abdomen. Pediatrics: Omnipaque Oral Solutions 9 and 12 administered orally in conjunction with Omnipaque 240 or Omnipaque 300 administered intravenously
• CT of the abdomen. Intra-articular Administration – Adults: Omnipaque 240, 300, and 350
• Arthrography. Body Cavity Administration –Adults: Omnipaque 240
• Endoscopic retrograde pancreatography (ERP) and endoscopic retrograde cholangiopancreatography (ERCP)
• Herniography
• Hysterosalpingography. Omnipaque 300
• Hysterosalpingography. Pediatrics: Omnipaque 240, 300, and 350 diluted
• Voiding cystourethrography (VCU).
IMPORTANT SAFETY INFORMATION
WARNING: RISKS WITH INADVERTENT
INTRATHECAL ADMINISTRATION OF
Omnipaque Injections 140 and 350 mgI/mL
See full Prescribing Information for complete Boxed Warning.
Omnipaque Injections 140 and 350 are contraindicated for intrathecal use.
Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema.
https://www.gehealthcare.com/en/products/contrast-media/omnipaque |
